{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:25:34Z","timestamp":1787019934765,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["125184"],"award-info":[{"award-number":["125184"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Migraine is a disorder associated with neuropeptide release, pain and inflammation. Tau protein has recently been linked to inflammatory diseases and can be influenced by neuropeptides such as CGRP, a key neurotransmitter in migraine. Here, we report serum concentrations of total-tau protein in migraine patients and healthy controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this cross-sectional study, interictal blood samples from\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200992 patients with episodic migraine (EM),\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200993 patients with chronic migraine (CM), and\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200942 healthy matched controls (HC) were studied. We assessed serum total-tau protein (t-tau) and for comparison neurofilament light chain protein (NfL), glial fibrillary acidic protein (GFAP), and ubiquitin carboxy-terminal hydrolase L (UCH-L1) concentrations using the Neurology 4-plex kit, on a single molecule array HD-X Analyzer (Quanterix Corp Lexington, MA). Matched serum\/cerebrospinal fluid (CSF) samples were used for post-hoc evaluations of a central nervous system (CNS) source of relevant findings. We applied non-parametric tests to compare groups and assess correlations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Serum t-tau concentrations were elevated in EM [0.320 (0.204 to 0.466) pg\/mL] and CM [0.304 (0.158 to 0.406) pg\/mL] patients compared to HC [0.200 (0.114 to 0.288) pg\/mL] (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002 vs. EM;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.025 vs. CM). EM with aura [0.291 (0.184 to 0.486 pg\/mL);\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.013] and EM without aura [0.332 (0.234 to 0.449) pg\/mL;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008] patients had higher t-tau levels than HC but did not differ between each other. Subgroup analysis of CM with\/without preventive treatment revealed elevated t-tau levels compared to HC only in the non-prevention group [0.322 (0.181 to 0.463) pg\/mL;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009]. T-tau was elevated in serum (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.028) but not in cerebrospinal fluid (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.760). In contrast to t-tau, all proteins associated with cell damage (NfL, GFAP, and UCH-L1), did not differ between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Migraine is associated with t-tau elevation in serum but not in the CSF. Our clinical study identifies t-tau as a new target for migraine research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-023-01663-5","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T05:03:06Z","timestamp":1695099786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Serum tau protein elevation in migraine: a cross-sectional case\u2013control study"],"prefix":"10.1186","volume":"24","author":[{"given":"Lucas Hendrik","family":"Overeem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Raffaelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Fleischmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"S\u00fc\u00dfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Vogelgesang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra Maleska","family":"Maceski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athina","family":"Papadopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Ruprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirja","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Arkuszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Tenenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"issue":"10100","key":"1663_CR1","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"Collaborators; GDaIIaP","year":"2017","unstructured":"Collaborators; GDaIIaP (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390(10100):1211\u20131259","journal-title":"Lancet"},{"issue":"19","key":"1663_CR2","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"AM Migraine","year":"2020","unstructured":"Migraine AM (2020) N Engl J Med 383(19):1866\u20131876","journal-title":"N Engl J Med"},{"issue":"8","key":"1663_CR3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/s41582-019-0216-y","volume":"15","author":"L Edvinsson","year":"2019","unstructured":"Edvinsson L, Haanes KA, Warfvinge K (2019) Does inflammation have a role in migraine? Nat Rev Neurol 15(8):483\u2013490","journal-title":"Nat Rev Neurol"},{"key":"1663_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2023.106072","volume":"180","author":"L Biscetti","year":"2023","unstructured":"Biscetti L, Cresta E, Cupini LM, Calabresi P, Sarchielli P (2023) The putative role of neuroinflammation in the complex pathophysiology of migraine: from bench to bedside. Neurobiol Dis 180:106072","journal-title":"Neurobiol Dis"},{"issue":"8","key":"1663_CR5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1474-4422(19)30185-1","volume":"18","author":"M Ashina","year":"2019","unstructured":"Ashina M, Hansen JM, Do TP, Melo-Carrillo A, Burstein R, Moskowitz MA (2019) Migraine and the trigeminovascular system-40 years and counting. Lancet Neurol 18(8):795\u2013804","journal-title":"Lancet Neurol"},{"issue":"6","key":"1663_CR6","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.3390\/ph3061966","volume":"3","author":"A Pardutz","year":"2010","unstructured":"Pardutz A, Schoenen J (2010) NSAIDs in the acute treatment of migraine: a review of clinical and experimental data. Pharmaceuticals (Basel) 3(6):1966\u20131987","journal-title":"Pharmaceuticals (Basel)"},{"issue":"Suppl 4","key":"1663_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/head.12601","volume":"55","author":"C Cameron","year":"2015","unstructured":"Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A et al (2015) Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache 55(Suppl 4):221\u2013235","journal-title":"Headache"},{"issue":"1","key":"1663_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3390\/biomedicines10010076","volume":"10","author":"E Spekker","year":"2021","unstructured":"Spekker E, Tanaka M, Szab\u00f3 \u00c1, V\u00e9csei L (2021) Neurogenic inflammation: the participant in migraine and recent advancements in translational research. Biomedicines 10(1):76","journal-title":"Biomedicines"},{"issue":"9\u201310","key":"1663_CR9","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1097\/00001756-199707070-00029","volume":"8","author":"KW Johnson","year":"1997","unstructured":"Johnson KW, Schaus JM, Durkin MM, Audia JE, Kaldor SW, Flaugh ME et al (1997) 5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. NeuroReport 8(9\u201310):2237\u20132240","journal-title":"NeuroReport"},{"issue":"6","key":"1663_CR10","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/ana.25731","volume":"87","author":"N Hadjikhani","year":"2020","unstructured":"Hadjikhani N, Albrecht DS, Mainero C, Ichijo E, Ward N, Granziera C et al (2020) Extra-axial inflammatory signal in parameninges in migraine with visual aura. Ann Neurol 87(6):939\u2013949","journal-title":"Ann Neurol"},{"issue":"3","key":"1663_CR11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ana.410200303","volume":"20","author":"MF Beal","year":"1986","unstructured":"Beal MF, Mazurek MF, Chattha GK, Svendsen CN, Bird ED, Martin JB (1986) Neuropeptide Y immunoreactivity is reduced in cerebral cortex in Alzheimer\u2019s disease. Ann Neurol 20(3):282\u2013288","journal-title":"Ann Neurol"},{"issue":"1","key":"1663_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.bj.2018.01.003","volume":"41","author":"C Laurent","year":"2018","unstructured":"Laurent C, Bu\u00e9e L, Blum D (2018) Tau and neuroinflammation: what impact for alzheimer\u2019s disease and tauopathies? Biomed J 41(1):21\u201333","journal-title":"Biomed J"},{"issue":"7673","key":"1663_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature24016","volume":"549","author":"Y Shi","year":"2017","unstructured":"Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W et al (2017) ApoE4 markedly exacerbates Tau-mediated neurodegeneration in a mouse model of Tauopathy. Nature 549(7673):523\u2013527","journal-title":"Nature"},{"key":"1663_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jaut.2019.04.003","volume":"101","author":"A Didonna","year":"2019","unstructured":"Didonna A, Cant\u00f3 E, Shams H, Isobe N, Zhao C, Caillier SJ et al (2019) Sex-specific Tau methylation patterns and synaptic transcriptional alterations are associated with neural vulnerability during chronic neuroinflammation. J Autoimmun 101:56\u201369","journal-title":"J Autoimmun"},{"issue":"1","key":"1663_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.nbd.2006.02.006","volume":"23","author":"KJ Gurney","year":"2006","unstructured":"Gurney KJ, Estrada EY, Rosenberg GA (2006) Blood-brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation. Neurobiol Dis 23(1):87\u201396","journal-title":"Neurobiol Dis"},{"issue":"16","key":"1663_CR16","doi-asserted-by":"publisher","first-page":"8929","DOI":"10.3390\/ijms22168929","volume":"22","author":"G Yamanaka","year":"2021","unstructured":"Yamanaka G, Suzuki S, Morishita N, Takeshita M, Kanou K, Takamatsu T et al (2021) Role of neuroinflammation and blood-brain barrier permutability on migraine. Int J Mol Sci 22(16):8929","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1663_CR17","doi-asserted-by":"publisher","first-page":"8861","DOI":"10.1038\/s41598-021-88237-0","volume":"11","author":"F Corrigan","year":"2021","unstructured":"Corrigan F, Cernak I, McAteer K, Hellewell SC, Rosenfeld JV, Turner RJ et al (2021) NK1 antagonists attenuate tau phosphorylation after blast and repeated concussive injury. Sci Rep 11(1):8861","journal-title":"Sci Rep"},{"issue":"8","key":"1663_CR18","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1212\/01.wnl.0000240119.29939.c7","volume":"67","author":"K Jin","year":"2006","unstructured":"Jin K, Takeda A, Shiga Y, Sato S, Ohnuma A, Nomura H et al (2006) CSF tau protein: a new prognostic marker for Guillain-Barr\u00e9 syndrome. Neurology 67(8):1470\u20131472","journal-title":"Neurology"},{"issue":"5","key":"1663_CR19","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s10072-012-1092-z","volume":"34","author":"XK Wang","year":"2013","unstructured":"Wang XK, Zhang HL, Meng FH, Chang M, Wang YZ, Jin T et al (2013) Elevated levels of S100B, tau and pNFH in cerebrospinal fluid are correlated with subtypes of Guillain-Barr\u00e9 syndrome. Neurol Sci 34(5):655\u2013661","journal-title":"Neurol Sci"},{"key":"1663_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/164_2018_201","volume":"255","author":"L Edvinsson","year":"2019","unstructured":"Edvinsson L (2019) Role of CGRP in Migraine. Handb Exp Pharmacol 255:121\u2013130","journal-title":"Handb Exp Pharmacol"},{"issue":"7","key":"1663_CR21","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/head.14352","volume":"62","author":"Z Bertels","year":"2022","unstructured":"Bertels Z, Mangutov E, Conway C, Siegersma K, Asif S, Shah P et al (2022) Migraine and peripheral pain models show differential alterations in neuronal complexity. Headache 62(7):780\u2013791","journal-title":"Headache"},{"key":"1663_CR22","doi-asserted-by":"publisher","first-page":"e63076","DOI":"10.7554\/eLife.63076","volume":"10","author":"Z Bertels","year":"2021","unstructured":"Bertels Z, Singh H, Dripps I, Siegersma K, Tipton AF, Witkowski WD et al (2021) Neuronal complexity is attenuated in preclinical models of migraine and restored by HDAC6 inhibition. Elife 10:e63076","journal-title":"Elife"},{"key":"1663_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108017","volume":"168","author":"H Na","year":"2020","unstructured":"Na H, Gan Q, McParland L, Yang JB, Yao H, Tian H et al (2020) Characterization of the effects of calcitonin gene-related peptide receptor antagonist for Alzheimer\u2019s disease. Neuropharmacology 168:108017","journal-title":"Neuropharmacology"},{"issue":"6","key":"1663_CR24","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.biopha.2009.06.009","volume":"64","author":"ZH Zhang","year":"2010","unstructured":"Zhang ZH, Fang XB, Xi GM, Li WC, Ling HY, Qu P (2010) Calcitonin gene-related peptide enhances CREB phosphorylation and attenuates tau protein phosphorylation in rat brain during focal cerebral ischemia\/reperfusion. Biomed Pharmacother 64(6):430\u2013436","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"1663_CR25","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.pain.2010.10.002","volume":"152","author":"XC Zhang","year":"2011","unstructured":"Zhang XC, Kainz V, Burstein R, Levy D (2011) Tumor necrosis factor-\u03b1 induces sensitization of meningeal nociceptors mediated via local COX and p38 MAP kinase actions. Pain 152(1):140\u2013149","journal-title":"Pain"},{"issue":"46","key":"1663_CR26","doi-asserted-by":"publisher","first-page":"18985","DOI":"10.1073\/pnas.1215435109","volume":"109","author":"A Tozzi","year":"2012","unstructured":"Tozzi A, de Iure A, Di Filippo M, Costa C, Caproni S, Pisani A et al (2012) Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. Proc Natl Acad Sci U S A 109(46):18985\u201318990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt 1","key":"1663_CR27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/brain\/awn307","volume":"132","author":"HW Schytz","year":"2009","unstructured":"Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M (2009) PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 132(Pt 1):16\u201325","journal-title":"Brain"},{"key":"1663_CR28","unstructured":"H. Lundbeck A\/S (2023) Lundbeck announces positive phase II Proof of Concept results with Lu AG09222 in migraine prevention (Corporate Release No 740). Retrieved from: https:\/\/mb.cision.com\/Main\/18215\/3754245\/1995698.pdf"},{"issue":"4","key":"1663_CR29","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/00001756-200203250-00030","volume":"13","author":"M Knutsson","year":"2002","unstructured":"Knutsson M, Edvinsson L (2002) Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia. NeuroReport 13(4):507\u2013509","journal-title":"NeuroReport"},{"issue":"595","key":"1663_CR30","doi-asserted-by":"publisher","first-page":"eaba7394","DOI":"10.1126\/scitranslmed.aba7394","volume":"13","author":"AW Schaler","year":"2021","unstructured":"Schaler AW, Runyan AM, Clelland CL, Sydney EJ, Fowler SL, Figueroa HY et al (2021) PAC1 receptor-mediated clearance of tau in postsynaptic compartments attenuates tau pathology in mouse brain. Sci Transl Med 13(595):eaba7394","journal-title":"Sci Transl Med"},{"issue":"8","key":"1663_CR31","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H (2019) Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 90(8):870\u2013881","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"1663_CR32","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0361-9230(03)00089-3","volume":"61","author":"KJ Lamers","year":"2003","unstructured":"Lamers KJ, Vos P, Verbeek MM, Rosmalen F, van Geel WJ, van Engelen BG (2003) Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients. Brain Res Bull 61(3):261\u2013264","journal-title":"Brain Res Bull"},{"issue":"2\u20134","key":"1663_CR33","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.neuint.2007.05.007","volume":"51","author":"R Setsuie","year":"2007","unstructured":"Setsuie R, Wada K (2007) The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem Int 51(2\u20134):105\u2013111","journal-title":"Neurochem Int"},{"key":"1663_CR34","doi-asserted-by":"crossref","unstructured":"(2018) Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38(1):1\u2013211","DOI":"10.1177\/0333102417738202"},{"key":"1663_CR35","unstructured":"Diener H-C, F\u00f6rderreuther S, Kropp P et al (2022) Therapie der Migr\u00e4neattacke und Prophylaxe der Migr\u00e4ne, S1-Leitlinie. DGN und DMKG, in: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. http:\/\/www.dgn.org\/leitlinien. Retrieved on August 10, 2023"},{"issue":"8","key":"1663_CR36","doi-asserted-by":"publisher","first-page":"4687","DOI":"10.1073\/pnas.071582498","volume":"98","author":"N Hadjikhani","year":"2001","unstructured":"Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, Fischl B et al (2001) Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A 98(8):4687\u20134692","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1663_CR37","volume":"2012","author":"M Kolarova","year":"2012","unstructured":"Kolarova M, Garc\u00eda-Sierra F, Bartos A, Ricny J, Ripova D (2012) Structure and pathology of tau protein in Alzheimer disease. Int J Alzheimers Dis 2012:731526","journal-title":"Int J Alzheimers Dis"},{"issue":"9","key":"1663_CR38","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1111\/ene.15428","volume":"29","author":"I Kmezic","year":"2022","unstructured":"Kmezic I, Samuelsson K, Finn A, Upate Z, Blennow K, Zetterberg H et al (2022) Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies. Eur J Neurol 29(9):2810\u20132822","journal-title":"Eur J Neurol"},{"key":"1663_CR39","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.expneurol.2014.07.008","volume":"261","author":"I Sotiropoulos","year":"2014","unstructured":"Sotiropoulos I, Lopes AT, Pinto V, Lopes S, Carlos S, Duarte-Silva S et al (2014) Selective impact of Tau loss on nociceptive primary afferents and pain sensation. Exp Neurol 261:486\u2013493","journal-title":"Exp Neurol"},{"issue":"2","key":"1663_CR40","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/ana.410280213","volume":"28","author":"PJ Goadsby","year":"1990","unstructured":"Goadsby PJ, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28(2):183\u2013187","journal-title":"Ann Neurol"},{"issue":"9","key":"1663_CR41","doi-asserted-by":"publisher","first-page":"7125","DOI":"10.1007\/s11033-020-05781-0","volume":"47","author":"S P\u00e9rez-Pereda","year":"2020","unstructured":"P\u00e9rez-Pereda S, Toriello-Su\u00e1rez M, Ocejo-Vinyals G, Guiral-Foz S, Castillo-Obeso J, Montes-G\u00f3mez S et al (2020) Serum CGRP, VIP, and PACAP usefulness in migraine: a case-control study in chronic migraine patients in real clinical practice. Mol Biol Rep 47(9):7125\u20137138","journal-title":"Mol Biol Rep"},{"issue":"2","key":"1663_CR42","doi-asserted-by":"publisher","first-page":"128","DOI":"10.4103\/0976-3147.131652","volume":"5","author":"Y Zlotnik","year":"2014","unstructured":"Zlotnik Y, Plakht Y, Aven A, Engel Y, Am NB, Ifergane G (2014) Alcohol consumption and hangover patterns among migraine sufferers. J Neurosci Rural Pract 5(2):128\u2013134","journal-title":"J Neurosci Rural Pract"},{"issue":"2","key":"1663_CR43","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.neulet.2008.07.052","volume":"443","author":"TF Gendron","year":"2008","unstructured":"Gendron TF, McCartney S, Causevic E, Ko LW, Yen SH (2008) Ethanol enhances tau accumulation in neuroblastoma cells that inducibly express tau. Neurosci Lett 443(2):67\u201371","journal-title":"Neurosci Lett"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01663-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01663-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01663-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T04:03:07Z","timestamp":1700366587000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01663-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1663"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01663-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3177691\/v1","asserted-by":"object"}]},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,19]]},"assertion":[{"value":"17 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LHO has nothing to declare. BR received speaker fees from Abbvie\/Allergan, Lilly, Lundbeck, Novartis, Teva, and grant support for research or education form Novartis, the German Migraine and Headache Society (DMKG) and the German Research Foundation (DFG). BR is member of the junior editorial board of The Journal of Headache and Pain, and editorial board of Frontiers in Neurology. RF received speaker fees from Novartis. MS has nothing to declare. AV has nothing to declare AMM has nothing to declare. KR received speaker fees from Bayer, travel grants from Guthy Jackson Charitable Foundation, and grant support for research or education from Novartis\u00a0Pharma, Merck Serono, German\u00a0Ministry of Education and Research,\u00a0European Union\u00a0(821283\u20132), Stiftung Charit\u00e9 (BIH Clinical Fellow Program) and Arthur Arnstein Foundation. WS, MK, MA, and ND are current or former employees of Novartis Pharma. AS received speaker fees from Teva and congress fees from Novartis. JK received speaker fees, research support, or travel support from or served on advisory boards for Swiss MS Society, Swiss National Research Foundation (320030_189140\/1), University of Basel, Progressive MS Alliance, Bayer, Biogen, Celgene, Merck, Novartis, Roche, and Sanofi. UR received speaker or consulting fees from Amgen, Allergan, Abbvie, Eli Lilly, Lundbeck, Novartis, Medscape, Pfizer, StreaMedUp, and Teva, and received grant support for research or education from Novartis (CHERUB01) and German Federal Ministry of Education and Research. UR is treasurer of the EHF and serves as associate editor of the Journal of Headache and Pain and Frontiers in Neurology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}